Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments
Journal of Crohn's and Colitis · 2023
DOI: 10.1093/ecco-jcc/jjad049 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Crohn's and Colitis, 2023. Verfasst von Maria M E Jongsma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Gastroenterology, Erasmus University Medical Center/Sophia Children's Hospital, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZonMw, Netherlands Organization for Health Research and Developmen, Pfizer.
Abstract (Originalsprache)
Background
Despite its efficacy, rational guidance for starting/stopping first-line biologic treatment in individual paediatric Crohn’s disease [CD] patients is needed. We assessed how serum immune profiles before and after first-line infliximab [FL-IFX] or conventional [CONV] induction therapy associate with disease remission at week 52.
Methods
Pre- [n = 86], and 10–14-week post-treatment [n = 84] sera were collected from patients with moderate-to-severe paediatric CD in the TISKids trial, randomized to FL-IFX [n = 48; five 5-mg/kg infusions over 22 weeks] or CONV [n = 43; exclusive enteral nutrition or oral prednisolone]; both groups received azathioprine maintenance. The relative concentrations of 92 inflammatory proteins were determined with Olink Proteomics; fold changes [FC] with |log2FC| > 0.5 after false discovery rate adjustment were considered significant.
Results
FL-IFX modulated a larger number of inflammatory proteins and induced stronger suppression than CONV; 18/30 proteins modulated by FL-IFX were not regulated by CONV. Hierarchical clustering based on IFX-modulated proteins at baseline revealed two clusters of patients: CD-hi patients had significantly higher concentrations of 23/30 IFX-modulated proteins [including oncostatin-M, TNFSF14, HGF and TGF-α], and higher clinical disease activity, C-reactive protein and blood neutrophils at baseline than CD-lo patients. Only 24% of CD-hi FL-IFX-treated patients maintained remission without escalation at week 52 vs 58% of CD-lo FL-IFX-treated patients. Similarly, 6% of CD-hi CONV-treated patients achieved remission vs 20% of CONV-treated CD-lo patients. Clustering based on immune profiles post-induction therapy did not relate to remission at week 52.
Conclusion
FL-IFX leads to stronger reductions and modulates more immune proteins than CONV. Stratification on pre-treatment profiles of IFX-modulated proteins directly relates to maintenance of remission without treatment escalation. Trial registration number NCT02517684.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Gastroenterology, Erasmus University Medical Center/Sophia Children's Hospital, Rotterdam, the Netherlands.
- Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus University Medical Center/Sophia Children's Hospital, Rotterdam, the Netherlands.
- Department of Pathology & Clinical Bioinformatics, Erasmus University Medical Center/Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Förderung
- ZonMw
- Netherlands Organization for Health Research and Developmen
- Pfizer
- TIMID
- Life Sciences & Health
- Samenwerkende Gezondheidsfondsen
Zitieren
APA
Jongsma, M. M. E., Costes, L. M. M., Tindemans, I., Cozijnsen, M. A., Raatgreep, R. H. C., van Pieterson, M., Li, Y., Escher, J. C., de Ridder, L., & Samsom, J. N. (2023). Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjad049
Vancouver
Jongsma MME, Costes LMM, Tindemans I, Cozijnsen MA, Raatgreep RHC, van Pieterson M, et al. Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments. Journal of Crohn's and Colitis. 2023. doi:10.1093/ecco-jcc/jjad049
BibTeX
@article{Jongsma2023,
author = {Jongsma, Maria M E and Costes, Lea M M and Tindemans, Irma and Cozijnsen, Martinus A and Raatgreep, Rolien H C and van Pieterson, Merel and Li, Yunlei and Escher, Johanna C and de Ridder, Lissy and Samsom, Janneke N},
title = {Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments},
journal = {Journal of Crohn's and Colitis},
year = {2023},
doi = {10.1093/ecco-jcc/jjad049}
}
EUVIMED